Loading...
•
Jun 30, 2023
Adverum Q2 2023 Earnings Report
Adverum completed enrollment of Phase 2 LUNA trial in wet AMD and reported second quarter 2023 financial results.
Key Takeaways
Adverum Biotechnologies announced the completion of enrollment in its Phase 2 LUNA trial evaluating Ixo-vec for wet AMD treatment and reported financial results for the second quarter ended June 30, 2023. The company's cash runway is projected into 2025.
Completed enrollment in Phase 2 LUNA trial evaluating Ixo-vec for wet AMD.
Combined OPTIC and LUNA trials will follow approximately 90 wet AMD subjects dosed with Ixo-vec out to five years.
Anticipate aflibercept protein levels for percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023.
Cash runway projected into 2025.
Forward Guidance
Adverum anticipates aflibercept protein levels for the percentage of cohort with a minimum of 14 weeks of follow-up as of data cutoff in late Q3 2023 and anticipates LUNA preliminary efficacy and safety data for percentage of cohort in Q4 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...